nach oben

Skeletal Radiology

Erschienen in:

01.03.2010 | Review Article

Benefits of molecular pathology in the diagnosis of musculoskeletal disease

Part II of a two-part review: bone tumors and metabolic disorders

verfasst von: Adrienne M. Flanagan, David Delaney, Paul O’Donnell

Erschienen in: Skeletal Radiology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The second part of this review, on the benefits of molecular pathology in the diagnosis disease, focuses on the genetics of bone tumors and metabolic disease. Unlike soft tissue tumors, the number of currently exploitable molecular abnormalities for diagnosing bone neoplasms is small, although the same gene rearrangements are found in primitive neuroectodermal tumor/Ewing sarcoma in both skeletal and extraskeletal sites. Compared with soft tissue tumors, genetic abnormalities, which are valuable to diagnosticians in skeletal disease, are often germline and post-zygotic aberrations rather than somatic translocations. In addition, the review highlights the range of disease entities classified as “osteoclast-rich lesions,” some of which harbor germline mutations. It also addresses the importance of phosphate metabolism in skeletal disorders including phosphaturic mesenchymal tumor, vitamin D-resistant rickets, and tumoral calcinosis.

Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 1999;18:783–8.CrossRefPubMed

Muller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007;121:199–205.CrossRefPubMed

Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007;39:1476–82.CrossRefPubMed

Selvarajah S, Yoshimoto M, Ludkovski O, Park PC, Bayani J, Thorner P, et al. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res. 2008;122:5–15.CrossRefPubMed

Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, et al. A molecular map of mesenchymal tumors. Genome Biol. 2005;6:R76.CrossRefPubMed

Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005;65:8142–50.CrossRefPubMed

Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004;4:45.CrossRefPubMed

Hameetman L, Rozeman LB, Lombaerts M, Oosting J, Taminiau AH, Cleton-Jansen AM, et al. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. J Pathol. 2006;209:501–11.CrossRefPubMed

Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol. 2005;6:599–607.CrossRefPubMed

10.

Bovee JV, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AH, Bakker E, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet. 1999;65:689–98.CrossRefPubMed

11.

Pannier S, Legeai-Mallet L. Hereditary multiple exostoses and enchondromatosis. Best Pract Res Clin Rheumatol. 2008;22:45–54.CrossRefPubMed

12.

Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature. 1989;340:692–6.CrossRefPubMed

13.

Delaney D, Diss TC, Presneau N, Hing S, Berisha F, Idowu BD, et al. GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol. 2009;22:718–24.CrossRefPubMed

14.

Okamoto S, Hisaoka M, Ushijima M, Nakahara S, Toyoshima S, Hashimoto H. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch. 2000;437:133–7.CrossRefPubMed

15.

Mazabraud A, Semat P, Roze R. A propos de l'association de fibromyxomes des tissus mous à la dysplasie fibreuse des os. Presse Med. 1967;75:2223–8.PubMed

16.

Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr. 1993;123:509–18.CrossRefPubMed

17.

Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A. 1992;89:5152–6.CrossRefPubMed

18.

Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325:1688–95.PubMed

19.

Idowu BD, Al-Adnani M, O'Donnell P, Yu L, Odell E, Diss T, et al. A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. Histopathology. 2007;50:691–704.CrossRefPubMed

20.

Fletcher CDM, Krishnan U, Mertens F. Pathology and genetics. Tumors of soft tissue and bone. In: Kleihues P, Sobin LH, editors. World Health Organization classification of tumors. Lyon: IARC Press; 2002.

21.

Kahn LB. Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma. Skeletal Radiol. 2003;32:245–58.PubMed

22.

Hazelbag HM, Fleuren GJ, vd Broek LJ, Taminiau AH, Hogendoorn PC. Adamantinoma of the long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis. Am J Surg Pathol. 1993;17:1225–33.CrossRefPubMed

23.

Hazelbag HM, Taminiau AH, Fleuren GJ, Hogendoorn PC. Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histological subtype, precursor lesion, and biological behavior. J Bone Joint Surg Am. 1994;76:1482–99.PubMed

24.

Kamineni S, Briggs TW, Saifuddin A, Sandison A. Osteofibrous dysplasia of the ulna. J Bone Joint Surg Br. 2001;83:1178–80.CrossRefPubMed

25.

Khanna M, Delaney D, Tirabosco R, Saifuddin A. Osteofibrous dysplasia, osteofibrous dysplasia-like adamantinoma and adamantinoma: correlation of radiological imaging features with surgical histology and assessment of the use of radiology in contributing to needle biopsy diagnosis. Skeletal Radiol. 2008;37:1077–84.CrossRefPubMed

26.

Lee RS, Weitzel S, Eastwood DM, Monsell F, Pringle J, Cannon SR, et al. Osteofibrous dysplasia of the tibia. Is there a need for a radical surgical approach? J Bone Joint Surg Br. 2006;88:658–64.CrossRefPubMed

27.

Pollandt K, Engels C, Kaiser E, Werner M, Delling G. Gsalpha gene mutations in monostotic fibrous dysplasia of bone and fibrous dysplasia-like low-grade central osteosarcoma. Virchows Arch. 2001;439:170–5.CrossRefPubMed

28.

Flanagan AM, Nui B, Tinkler SM, Horton MA, Williams DM, Chambers TJ. The multinucleate cells in giant cell granulomas of the jaw are osteoclasts. Cancer. 1988;62:1139–45.CrossRefPubMed

29.

Panoutsakopoulos G, Pandis N, Kyriazoglou I, Gustafson P, Mertens F, Mandahl N. Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts. Genes Chromosomes Cancer. 1999;26:265–6.CrossRefPubMed

30.

Oliveira AM, Hsi BL, Weremowicz S, Rosenberg AE, Dal Cin P, Joseph N, et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res. 2004;64:1920–3.CrossRefPubMed

31.

Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, Chen CJ, Neff JR, et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 2005;24:3419–26.CrossRefPubMed

32.

Oliveira AM, Perez-Atayde AR, Inwards CY, Medeiros F, Derr V, Hsi BL, et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol. 2004;165:1773–80.PubMed

33.

Bertoni F, Unni KK, Beabout JW, Sim FH. Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Am J Surg Pathol. 1997;21:153–63.CrossRefPubMed

34.

Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O'Connell JX, Huntsman D, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31:970–6.CrossRefPubMed

35.

Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 2001;28:125–6.CrossRefPubMed

36.

Jafarov T, Ferimazova N, Reichenberger E. Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism. Clin Genet. 2005;68:190–1.CrossRefPubMed

37.

Beneteau C, Cave H, Moncla A, Dorison N, Munnich A, Verloes A, et al. SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur J Hum Genet. 2009; doi:10.1038/ejhg.2009.4.

38.

Hanna N, Parfait B, Talaat IM, Vidaud M, Elsedfy HH. SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome. Clin Genet. 2009;75:568–71.CrossRefPubMed

39.

Van Capelle CI, Hogeman PH, van der Sijs-Bos CJ, Heggelman BG, Idowu B, Slootweg PJ, et al. Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatr. 2007;166:905–9.CrossRefPubMed

40.

Southgate J, Sarma U, Townend JV, Barron J, Flanagan AM. Study of the cell biology and biochemistry of cherubism. J Clin Pathol. 1998;51:831–7.CrossRefPubMed

41.

Idowu BD, Thomas G, Frow R, Diss TC, Flanagan AM. Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumors of the jaw. Br J Oral Maxillofac Surg. 2008;46:229–30.CrossRefPubMed

42.

De Lange J, van den Akker HP, van den Berg H. Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:603–15.CrossRefPubMed

43.

Aoki Y, Matsubara Y. Human development and the RAS/MAPK pathway. Seikagaku. 2007;79:34–8.PubMed

44.

Croonen EA, van der Burgt I, Kapusta L, Draaisma JM. Electrocardiography in Noonan syndrome PTPN11 gene mutation–phenotype characterization. Am J Med Genet A. 2008;146:350–3.PubMed

45.

Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA. The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child. 2007;92:128–32.CrossRefPubMed

46.

Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2006;78:279–90.CrossRefPubMed

47.

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500–5.CrossRefPubMed

48.

Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism—unique biological characteristics of FGF23. Bone 2007;40:1190–5.CrossRefPubMed

49.

Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.CrossRefPubMed

50.

Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656–63.CrossRefPubMed

51.

Consortium A. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345–8.CrossRef

52.

White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079–86.CrossRefPubMed

53.

Mikati MA, Melhem RE, Najjar SS. The syndrome of hyperostosis and hyperphosphatemia. J Pediatr. 1981;99:900–4.CrossRefPubMed

54.

Ziran N, Hill S, Wright ME, Kovacs J, Robey PG, Wientroub S, et al. Ribbing disease: radiographic and biochemical characterization, lack of response to pamidronate. Skeletal Radiol. 2002;31:714–9.CrossRefPubMed

55.

Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, et al. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med. 2005;83:33–8.CrossRefPubMed

56.

Arnold WH. Hereditary bone dysplasia with sarcomatous degeneration. Study of a family. Ann Intern Med. 1973;78:902–6.PubMed

57.

Douya H, Yokoyama R, Beppu Y, Hasegawa T. Malignant fibrous histiocytoma associated with diaphyseal medullary stenosis. Clin Orthop Relat Res. 2002;400:211–6.CrossRefPubMed

58.

Hardcastle P, Nade S, Arnold W. Hereditary bone dysplasia with malignant change. Report of three families. J Bone Joint Surg Am. 1986;68:1079–89.PubMed

59.

Kenan S, Abdelwahab IF, Hermann G, Klein MJ. Malignant fibrous histiocytoma associated with a bone infarct in a patient with hereditary bone dysplasia. Skeletal Radiol. 1998;27:463–7.CrossRefPubMed

60.

Norton KI, Wagreich JM, Granowetter L, Martignetti JA. Diaphyseal medullary stenosis (sclerosis) with bone malignancy (malignant fibrous histiocytoma): Hardcastle syndrome. Pediatr Radiol. 1996;26:675–7.CrossRefPubMed

61.

Martignetti JA, Desnick RJ, Aliprandis E, Norton KI, Hardcastle P, Nade S, et al. Diaphyseal medullary stenosis with malignant fibrous histiocytoma: a hereditary bone dysplasia/cancer syndrome maps to 9p21–22. Am J Hum Genet. 1999;64:801–7.CrossRefPubMed

62.

Martignetti JA, Gelb BD, Pierce H, Picci P, Desnick RJ. Malignant fibrous histiocytoma: inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21–22—evidence for a common genetic defect. Genes Chromosomes Cancer 2000;27:191–5.CrossRefPubMed

63.

Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, Paulussen M, et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol. 1999;17:1809–14.PubMed

64.

Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7:3977–87.PubMed

65.

Hisaoka M, Ishida T, Kuo TT, Matsuyama A, Imamura T, Nishida K, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol. 2008;32:452–60.CrossRefPubMed

66.

Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2002;20:2672–9.CrossRefPubMed

Titel: Benefits of molecular pathology in the diagnosis of musculoskeletal disease
Part II of a two-part review: bone tumors and metabolic disorders
verfasst von: Adrienne M. Flanagan
David Delaney
Paul O’Donnell
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Skeletal Radiology / Ausgabe 3/2010
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI: https://doi.org/10.1007/s00256-009-0758-y

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Benefits of molecular pathology in the diagnosis of musculoskeletal disease

Part II of a two-part review: bone tumors and metabolic disorders

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Twenty-degree-tilt radiography for evaluation of lateral humeral condylar fracture in children

Hematoma in the cervical ligamentum flavum. Report of a case and review of the literature

Progressive atlanto-axial subluxation in Behcet’s disease

Thank you to our reviewers of 2009

Evaluation of volume and solitary bone cyst remodeling using conventional radiological examination

Treating osteonecrosis with autologous bone marrow cells

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie